Mode
Text Size
Log in / Sign up
N/A N=35 Randomized Double-blind Treatment

The Effectiveness of SensAwake™ for Continue Positive Airway Pressure Treatment of Obstructive Sleep Apnea Patients

Obstructive Sleep Apnea

Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Jun 2018
Primary outcome: Primary: Compliance of Auto-CPAP Therapy — 41.8; 39.7 percentage of nights

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
SensAwake™ modification (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Chang Gung Memorial Hospital
Primary completion
Mar 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Compliance of Auto-CPAP Therapy
41.8; 39.7
SECONDARY
Average SA Detections
2.1; 0
SECONDARY
Average Pressures of Auto-CPAP Machine
6.9; 7.3
SECONDARY
90th Percentile Pressures of Auto-CPAP Machine
8.6; 9.2
SECONDARY
Average Leaks of Auto-CPAP Machine
41.3; 44.6
SECONDARY
90th Percentile Leaks of Auto-CPAP Machine
57.6; 58.9
SECONDARY
Residual Apnea-Hypopnea Index (AHI)
6.3; 5.0
SECONDARY
Time Used of Auto-CPAP Machine
213.1; 206.8
SECONDARY
Percentage of Day Used of Auto-CPAP Machine
87.1; 88.1
SECONDARY
Pittsburgh Sleep Quality Index (PSQI)
8.0; 8.0
SECONDARY
Epworth Sleepiness Score (ESS)
11.1; 12.1
SECONDARY
Nasal Obstruction Symptom Evaluation (NOSE)
14.6; 13.3

Summary

This study will investigate Obstructive Sleep Apnea (OSA) and an automatically Adjusting Positive Airway Pressure (APAP) device with new technology called SensAwake™. This requires experimental confirmation in a randomised controlled trial with crossover design, comparing compliance on standard APAP with compliance using APAP modified by the addition of the SensAwake™ modification on consecutive nights in participants with moderate-to-severe OSA.

Eligibility Criteria

Inclusion Criteria

  • Participants will be recruited from OSA patients who will remove CPAP himself without any notable reasons.

Exclusion Criteria

  • Unstable cardiovascular disease (untreated or resistant hypertension acceptable).
  • Inability to tolerate CPAP due to nasal obstruction or claustrophobia as determined by the study investigator.
  • Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as psychiatric disease, history of non compliance to medical regimens, or unwillingness to comply with study requirements.
  • Any known factor that result in mask taken of such as skin discomfort, nasal obstruction, water dripping inside the tubing system etc.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03294629). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search